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ABSTRACT

Vitamin B6 metabolism and transport were investigated using
activation of erythrocyte aspartate apotransaminase

(EGOT)

as a

measure of intracellular availability of active cofactor forms of B6.
Questions asked here address

the possibility that a form of B6 other

than pyridoxal or pyridoxal-51-phosphate

(PLP)

is

important in plasma

and that entry of PLP into tissues may not involve mechanisms
previously proposed.

In plasma,

two forms of vitamin B6,

pyridoxamine-51-phosphate and pyridoxamine,

were found to increase

EGOT activity to a greater extent than other vitamers.
with previous

findings,

Consistent

it v/as also found that the presence of plasma

inhibits EGOT activation by PLP.

Further investigations of EGOT

activation by PLP v/ith two anion channel blocking agents suggest that
anion channels may play a role

in PLP transport into the erythrocyte

only at high PLP concentrations.

This

is in contrast to previous

reports suggesting PLP entry into erythrocytes is entirely dependent
on anion channels.
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INTRODUCTION

Over the past fifteen years,

much attention has been focused on

Vitamin B6 metabolism and transport in vivo and in vitro in an
attempt to discern on a cellular level how the entire organism
utilizes

this essential cofactor.

Unresolved in the current

literature are questions regarding the
various

forms of B6,

relative

importance of the

the overall effect of the non-cofactor

interaction of the aldehyde forms of B6 with plasma and intracellular
proteins,

and the mode of B6

The term "Vitamin Bs"

transport into tissues.

is designated to include three different

molecular forms and their phosphorylated derivatives known together
as the B6 vitamers
1973).

These are:

pyridoxamine

(PM),

(IUPAC-IUB Commission on Biochemical Nomenclature
pyridoxine

(PN),

pyridoxine 5'-phosphate

qyridoxamine 5'-phosphate

and pyridoxal 5'-phosphate

(PLP)

(fig 1).

(PMP),

(PNP),

pyridoxal

(PL),

Normal human plasma

concentrations of the six B6 vitamers as measured by chromatography
and fluorometric analysis

(Lumeng et al 1930)

are shown in Table

It is generally recognized however that of the six vitamers,

only PLP

and in some cases PMP are active cofactors at the enzymatic

level

(Meister et al 1954).

as a

The majority of enzymes requiring B6

cofactor are essential to amino acid metabolism.
transaminases,

synthetases,

hydroxylases,

dehydratases.

In addition,

glycogen phosphorylase
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These include

decarboxylases and
in muscle and
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Figure 2.

Schiff base

formation.

Table 1..
Total:

B6 vitamer concentrations.
(100%)

124 +/- 29nM

PLP :

77 nil

(62%)

PN

:

19 nH

(15%)

PL

:

17 nM

(14%)

PH

:

6 nM

(5%)

PMP :

5 nM

(4%)

delta-amino levulenic acid synthetase

in the marrow require B6

for

activation.

A deficiency of vitamin B6
neuropathy,

convulsions,

is known to produce dermatitis,

renal and hepatic

function changes,

decreased growth and decreased antibody formation
Canham 1980).

Additionally,

(Sauberlich and

in the alcoholic patient,

B6

deficiency

has been implicated in liver disease,

peripheral neuropathy,

convulsions,

(Hines and Cowan 1970,

1980).

and sideroblastic anemia

In fact,

even without exposure to alcohol,

been shown to produce
in monkeys

anemia,

Bonjour

B6 deficiency has

fatty infiltration and cirrhosis of the liver

(Greenberg 1964,

Abe and Kishino 1982).

been suggestions that B6

status is

atherosclerosis,

caries,

altered hemostasis,

(Greenberg 1964,

Sauberlich and Canham 1980).

There have also

related to nephrolithiasis,
and immunologic changes
Nonetheless,

a precise

daily dietary requirement of vitamin B6 has not been established.
The vitamin B6

requirement has been estimated to be 1.5 mg of

3

/

pyridoxine per 100 gm of dietary protein which translates into an RDA
of 1.6-2.2 mg of PN per day depending on age and sex
Dietary Allowances,

1980).

(Committee on

No signs or symptoms of PN toxicity are

presently recognized in adults.

However,

studies with beagles given

150mg/kg/day demonstrated neurological changes v/ithin two to six
weeks

(Hoover and Carlton 1981)

and Unna1s

(1940)

early observations

with rats showed 3gm/kg of PN produces convulsions and death within
24 hours.

Much of the interest

in vitamin B6 pharmacology and metabolism

originates from suggestions of its usefulness in therapy of certain
vitamin B6-responsive disorders
addition,

B6

(i.e.

dependency states).

In

therapy may be required for the treatment of simple

deficiency states due to disorders of absorption and utilization.

Specifically,

pyridoxine administration has been shown to be

helpful in certain gases of sideroblastic anemia,
drug induced defiencies
cycloserine,
Additionally,

(i.e.

penicillamine,

secondary to INH,

homocystinuria,

and

hydralazine,

or oral contraceptive administration).

it has been suggested that hepatic cell damage

secondary to alcohol abuse may be
(Lumeng and Li 1974,

responsive

Bonjour 1980)

to B6 administration

and that sickle cell disease

patients may benefit from pharmacological doses of B6 because of the
in vitro anti-sickling effect of pyridoxal and pyridoxal phosphate
(Zaugg et al 1977,

Kark et al 1978).

Thus,

the importance of

elucidating the precise mechanisms of B6 metabolism and hov; they may
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be advantageously manipulated is underscored.

Identification of the particular B6 vitamers which are most able
to produce a desired response

is essential.

Pyroxidine is

the B6

vitamer presently used pharmacologically and orally administered PN
is well absorbed from the jejunem
Anderson

(1980)

argues

oxidation to PL,

et al

(1980)

demonstrate

that the

liver is

for PN metabolism resulting in a net rise

plasma concentrations of PL,
pyridoxic acid.

Although

that erythrocytes are a major site of PN

Lumeng,

primarily responsible

(Brain and Booth 1964).

PLP,

and the

inactive metabolite,

This group further reports that administration of

lOOmg of pyridoxine per day for three weeks to healthy adults
in a steady state

results

level within one week of a six to seven-fold rise

in plasma PLP concentration and a twelve-fold rise
concentration.

in

At the tissue level,

in PL

orally administered PN produces

a sharp rise within hours in PL and PLP concentrations within the RBC
(Anderson et al 1971).

Important to the understanding of B6 vitamer activities
intracellularly and in plasma is the covalent binding of PL and PLP
to proteins.

The reversible Schiff base

primary amines at neutral pH's
recognized over a century ago
(1958)
PLP,

formation by aldehydes with

is a well described reaction first
(fig 2,

Schiff 1864).

first proposed the binding of the aldehyde

to the

formation.

free amino groups of bovine
Subsequently,

Christensen

forms of B6,

serum albumin by Schiff base

he and his coworkers were able to
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PL and

demonstrate the binding of PLP to albumin in a molar ratio of two to
one

(Dempsey 1962).

hydrolysis

Borohydride reduction followed by protein

revealed the binding by PLP to be with two epsilon-amino

groups of lysine residues.

These

the case with human albumin

(Lumeng et al 1974,

1974).

also found that the globulins constitute

Lumeng et al

(1974)

findings were

later confirmed to be
and Anderson et al

a significant portion of plasma binding capacity in vitro at high PLP
concentrations and that the total capacity of plasma to bind PLP is
in the range of 3 mM,

which far exceeds the normal plasma

concentration of this vitamer.

Dempsey

(1962)

points out however

that at such supraphysiologic PLP concentrations,

PLP binds

nonspecifically to albumin in a ratio exceeding two to one.

Thus,

any calculation of the plasma PLP binding capacity at high PLP
concentrations v/ill reflect binding potential not realized
physiologically.

Although the
reversible,

the

formation of Schiff bases is well known to be
reversibility of PLP binding to plasma proteins has

been the source of some confusion.

Christensen (1961)

reversibility of the PLP-albumin Schiff base
investigations.

Lumeng,

et al

(1974),

conflicting experimental findings
Schiff base

confirms

formation in his

however,

the

initial

report tv/o

regarding the reversibility of

formation which they fail to resolve.

They report the

results of a dialysis experiment which appear to show that PLP bound
to albumin is not dialyzable.

A separate experiment in the same

paper convincingly demonstrates,

however,
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that virtually all of the

PLP bound to albumin is hydrolyzable by alkaline phosphatase whether
the alkaline phosphatase is free in solution or separated from the
PLP-albumin complex by a dialysis membrane.

From the latter

experiment they conclude that albumin bound PLP is indeed in
equilibrium with free PLP in solution allowing membrane permeation by
albumin bound PLP.

However, without explanation, many of their

subsequent conclusions (Lumeng et al 1980) are drawn by an inference
from the first experiment that since PLP was found to be "nondialyzable," it must therefore be irreversibly bound.

For example,

they state that Schiff base formation prevents PLP from being
transported into erythrocytes.

This may be true from a static

viewpoint but may not be true in the actual dynamic equilibrium.

The

kinetics of PLP-albumin dissociation have not been adequately studied
to establish this point.
plasma PLP,

Furthermore,

in a discussion of the fate of

they state that although PLP is found in the urine,

it

cannot arrive there by glomerular filtration since it's "not
dialyzable."

Clearly,

the conceptual model derived from their

dialysis experiment is a source of misdirection for themselves and
perhaps others.

Pyridoxal phosphate is the B6 vitamer which activates B6 dependent
enzymes and it is also the vitamer found in the highest concentration
in plasma.

However,

it is unclear if the PLP in plasma enters cells

to combine with apoenzymes or whether another plasma vitamer enters
tissues and activates apoenzymes after conversion to an active form.
There remain two unexplained problems in the understanding of how
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plasma PLP might enter cells.

PLP is an organic phosphate and it is

well recognized that such anions do not readily cross cell membranes
without a specific transport mechanism.
been demonstrated for PLP.

Such a mechanism has not

Also because the

total plasma

concentration of PLP is well below the plasma protein binding
capacity for PLP,

the amount of free PLP in solution may actually be

less than any other B6 vitamer.
but it questions
vitamer.

the

This may not affect PLP transport,

logic of emphasizing PLP as the principle B6

Experiments directed at determining the

activation potentials for the B6 vitamers,
concentration in plasma,

relative enzyme

the actual free PLP

and the mechanism of PLP transport across

cell membranes are thus essential to understanding the physiology of

b6-

Experiments studying B6 metabolism at a cellular level have been
carried out using cultured tumor cells

%

rabbit choroid plexus
Erythrocytes are the
is based.

(Pal and Christensen 1961),

)

(Spector and Greenwald 1978),

and erythrocytes.

tissue upon which the majority of the

literature

Whether the findings with erythrocytes can be generalized

to the other cells of the body is not known;
the model tissue

they remain nonetheless

for these investigations.

The erythrocyte has several important properties affecting its
metabolism of vitamin B6.
and an oxidase,

Three enzymes,

a phosphatase,

a kinase,

have been identified in erythrocytes which appear to

play an essential role in B6 metabolism.
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Yamada and Tsuji
phosphatase able

(1968)

first demonstrated a membrane bound

to cleave PLP to PL and inorganic phosphate.

Characterizing this enzyme,

Lumeng and Li

(1974)

have shov/n that 80

mM phosphate is inhibitory to the phosphatase activity.
suggested that acetaldehyde,
the phosphatase.

the ethanol metabolite,

Their later work

acetaldehyde may have

(Lumeng 1978)

They also

may potentiate

indicates that

this effect by displacing PLP from its

protective protein binding.

Mitchell et al

(1976)

also suggested

from their in vivo studies in alcoholics that ethanol is responsible
for increased PLP degradation and by inference
activity.

Many of the experiments

increased phosphatase

in the literature which focus on

PLP transport into erythrocytes take advantage of the phosphate
inhibition of the phosphatase
Bs

transport.

to examine the

role of this enzyme in

The data derived from such experiments is analyzed

with respect to alterations in the
vitamer concentration.

intracellular phosphorylated

Unfortunately,

it is also well documented

that phosphate stimulates red cell glycolysis.

This

results

in

increased synthesis and decreased catabolism of ATP and other organic
phosphates

(Rose and Warms 1966,

Rubinstein 1973).

The role

Beutler 1970,

Warrendorf and

this plays in altering B6 metabolism has

not been investigated.

The two enzymes necessary for interconversion of the B6 vitamers
have been well studied.

The enzyme pyridoxal kinase

(EC 2.7.2.35)

uses as substrate either ATP or ADP and is capable of phosphorylating
PL,

PM,

and PN

(McCormick et al 1961,
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Hamfelt 1967).

It is

competitively inhibited by the substrate deoxypyridoxine
is itself slowly phosphorylated to DOPNP
Furukawa

(1981)

has also shown that,

PL at high concentrations inhibits
formation at a non-active site.
reversed by dialysis.
the

(DOPM) which

(McCormick and Snell 1961).

at least with microbial kinase,

its activity by Schiff base

This inhibition,

Solomon and Hillman

(1975)

they note,
have

is

investigated

in vivo regulation of pyridoxal kinase activity and find that

orally administered PN induces increased kinase activity in young
erythrocytes.

The oxidase

(EC 1.4.3.5)

oxidizes PMP and PNP to PLP
phosphorylated vitamers,
When Lumeng and Li

is an flavin-dependent enzyme which
(Wada and Snell 1961).

The non-

PM and PN are minimally reactive substrates.

(1974) measured the combined activities of the

kinase and oxidase by measuring intracellular PLP concentration after
incubation with PL,

PN,

or PNP,

they found decreasing PLP content

with increasing substrate concentrations.
kinase or oxidase or both are

They concluded that the

subject to substrate inhibition.

investigations of the oxidase by Wada and Snell
absence of substrate

(1961)

indicate

The
the

inhibition or inhibition by non-phosphorylated

vitamers.

Whether there are mechanisms
unclear.

for vitamin B6 homeostasis

is

The observed effects of substrates and products on the

phosphatase,

kinase,

and oxidase are suggestive that these enzymes

may play a role in maintaining homeostasis but
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this

is presently

unresolved.

Another important property of erythrocytes

is the ability of

hemoglobin to bind considerable quanitities of PL and PLP by
reversible Schiff base formation.

This has much the

same

sequestering effect on PL and PLP intracellularly that albumin has
extracellularly.

Borohydride reduction and further analysis have

demonstrated that PL forms a Schiff base preferentially with the
terminal amino group of the alpha-chain of hemoglobin and PLP with
the beta-chain

(Benesch et al 1973).

Oxygen dissociation curves of

hemoglobin in the presence of PL and PLP indicate

that the binding of

PL to hemoglobin lowers the p50 and PLP binding raises the p50
(Benesch et al 1973).

This and the finding that PL or PLP binding

inhibits sickle hemoglobin polymerization have
using B6

in sickle cell patients

(Beutler et al 1972,

to prevent erythrocyte sickling

Kark et al 1978).

proven therapeutically fruitful,

raised the question of

Although use of PN has not

perhaps the use of other vitamers or

modification of erythrocyte B6 metabolism would increase the effect
of hemoglobin binding in vivo.

Investigations in the current literature have examined some of
these issues.

For most,

PLP content of plasma

the assumption is made that since the total

(including protein bound PLP)

among the vitamers and since it is

is the highest

the active coenzyme,

by some means cross the cellular membrane.

then PLP must

Because the erythrocyte

has a membrane bound phosphatase able to cleave extracellular PLP
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(in

addition to intracellular PLP)
v/hich is able

to PL and a kinase

intracellularly

to resynthesize PLP from PL and ATP,

investigations over the past two decades have
asking whether PLP is

transported across

many

focused on the question

the membrane

intact or is

cleaved and reformed intracellarly.

Suzue and Tachibana

(1970)

investigated this using a mixture of

14C-PLP and 32P-PLP.

They found the

32P to be the

the extracellular ratio and concluded from this

same as

intracellular ratio of 14C to

that PLP must be transported intact across the cell membrane.

They

fail to elaborate on their reasoning but presumably if PLP were
cleaved extracellularly and resynthesized intracellularly,

the

probability would be high that resynthesis would occur with non¬
radioactive phosphate.
14C-PLP relative

This v/ould cause an increase in the amount of

to 32P-PLP intracellularly which they did not

observe.

Likewise,

Spector and Greenwald (1978)

attempted to show that

accumulation of PLP in rabbit cerebrospinal fluid is dependent on a
dephosphorylation-rephosphorylation mechanism.

They found in vivo

that intravenous injection of the doubly-labeled

[3H,32P]-PNP

resulted in accumulation of 3H-PLP in the CSF without accumulation of
32P-phosphate.

They also report that the accumulation of PLP in CSF

is prevented by DOPN,

the pyridoxal kinase

inhibitor.

This was

attributed to the failure to resynthesize PLP once PL had entered the
CSF.

These experiments

fails to discriminate,
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however,

betv/een the

proposed mechanism of dephosphorylation prior to trans-membrane
passage followed by rephosphorylation and the alternative

that the

phosphorylated vitamer may enter the CSF intact only to be subject to
the activities of both a phosphatase and a kinase

resulting in a net

replacement of radioactive phosphate with non-radioactive phosphate.

Using erythrocytes,

Lumeng et al

(1974)

attempted to demonstrate

that cleavage of PLP to PL by the membrane bound phosphatase
necessary for its transport across the cell-membrane.
saline

is

In normal

they found 22% to the PLP added to the medium was

intracellular after incubation whereas 38% remained extracellular.
The remaining 40% of unrecovered PLP was presumed hydrolyzed by
phosphatase.

When the experiment was conducted with 80 mM phosphate

to inhibit the phosphatase,

18% of the added PLP was

intracellularly after incubation.

Extracellularly,

still found
77% of the added

PLP was recovered leaving only 5% unrecovered thus indicating
significant phosphatase inhibition.

From this data they concluded

that PLP cannot cross the erythrocyte membrane intact but that
must first be cleaved by phosphatase

to PL.

However,

it

they fail to

account for the 18% of PLP that enters the cells with the phosphatase
"inhibited" versus the 22% with the phosphatase active.
can be accounted for in two ways:

Indeed,

this

either 80 mM phosphate does not

fully inhibit phosphatase or another mechanism for transport of PLP
into erythrocytes obtains.

In either case,

their conclusion that

phosphatase activity is essential cannot be drawn with certainty from
their data.

In fact,

Maeda et al

(1976)

13

concluded from their similar

experiments that intact PLP enters erythrocytes by passive diffusion.
Using 160 mM phosphate buffer as an incubation medium,

they

demonstrated increasing intracellular PLP concentrations over time
with minimal loss of total PLP in the system.

Furthermore,

they

strengthen their argument for passive diffusion of PLP into
erythrocytes by demonstrating that the

initial velocity of PLP uptake

is linear with respect to PLP concentration.

The studies by Suzue and Tachibana
suggested PLP enters erythrocytes

(1968)

and Maeda

intact whereas

studies by Spector and Greenwald (1978)

(1976)

the subsequent

and Lumeng et al

(1974) were

not convincing that phosphatase activity is essential for transport.
Thus a need for further investigation is clearly indicated.

One

mechanism by which PLP could enter tissues without prior cleavage
by direct passage through membrane anion channels.

is

This has been

investigated using anion channel blocking agents.

Cabantchik and Rothstein

(1974)

developed the use of

4,4!-diisothiocyano- 2,2'-stilbene disulfonic acid
found to be a non-penetrating,
of erythrocyte anion channels.
membrane permeation by PLP

(DIDS) which they

highly specific and reactive blocker
They later found that DIDS prevented

(Cabantchik et al 1975).

Further

experiments characterizing the anion channel showed it is a single
protein isolable
DIDS binds

in membrane vesicles

to free amines,

(Wolosin et al 1977).

Cabantchik et al

(1975)

Because

proposed that the

anion channel protein has a free amino group as part of its active
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site.

And because PLP also binds to free amino groups,

conducted experiments to determine
channel.

the effect of PLP on the anion

They found that like DIDS,

of anions across

the membrane.

this group

PLP could also inhibit the

Furthermore,

flux

they found that elution

of the PLP from its binding sites reversed the effect on anion flux
unless PLP was bound irreversibly to amines by borohydride reduction
(Rothstein et al 1976).
erythrocytes,

Interestingly,

Kark and Hicks

(1930)

in their studies of sickle

found an increase

in anion

permeability of the membrane anion channels when compared to normal
cells.

This finding raises questions

channels is

regarding how flux through the

regulated in the normal and abnormal erythrocyte and hov/

such regulatory mechanisms might affect passage of PLP through the
membrane.

One of the major impediments to progress in the

field of B6

physiology has been the development of an accurate means of measuring
vitamer concentrations
environments.
chemical,

in the

intracellular and extracellular

A number of different assays have been used including

fluorometric

microbiological,

(Chauhan and Dakshinamurti 1979),

and enzymatic.

The direct chemical and fluorometric

measurements are inherently difficult because of the low vitamer
concentrations studied,
protein binding sites,

the variable elution of PL and PLP from their
and the instability of certain vitamers.

The

microbiological techniques often lack specificity among vitamers or
are insensitive to vitamers requiring assay.

As a means of assessing

the ability of a given vitamer to effect apoenzyme activation,
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the

enzymatic assays are quite useful.

Erythrocytes contain readily

measurable quantities of the PLP-dependent aspartate-oxaloacetate
transaminase
This enzyme

(EGOT,
is

normal adults

EC 2.6.1.1,

Meister et al 1954,

Walsh 1966).

found to be only 50-70% saturated by cofactor in
(Solomon and Hillman 1978) making it useful for in vivo

and in vitro supplementation studies.

It has been found that PMP is

also able to activate EGOT but that PMP and DOPNP inhibit EGOT
activity
(1975)

(Meister et al 1954).

Furthermore,

Solomon and Hillman

demonstrated that orally administered PM can induce an

increase

in the

total EGOT activity.

Interestingly,

they also

observed a transient drop in EGOT activity within hours after oral PN
or PLP administration.

This was felt to be suggestive of reversible

inactivation of the enzyme by non-specific Schiff base formation
followed by redistribution to the active sites within a few days.
They have also shown that in spite of a rapid rise in intracellular
PL and PLP concentrations after an oral PN dose
1971),

the rise

(Anderson et al

in EGOT activity occurs 27-48 hours

and Hillman 1979).

later

(Solomon

This last finding in itself raises questions

regarding the kinetics of the vitamer reactions and interactions
which will be addressed later.

Using the assay of EGOT as an index of PLP or PMP entry into
tissues or entry of other vitamers followed by conversion to an
active form,

the experiments described here demonstrate that in

plasma there

is marked variation of EGOT activation by the various

vitamers and that blocking the erythrocyte anion channels does not
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V

completely prevent entry of PLP into the cell.
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II.

EXPERIMENTAL

All reagents were obtained from Sigma Chemical Co.
exception of 3-(N-morpholino)propanesulfonic acid
obtained from Calbiochem Inc.,
2,21-disulfonic acid (SITS)

4-acetomido,

with the

(MOPS)

which was

4-isothiocyanostilbene

and

4,4'-diisothiocyanostilbene-2,21-disulfonic acid (DIDS) which were
obtained from ICN Pharmaceuticals.

Solutions of the B6 vitamers were made up to a concentration of
approximately 45 mM,

pH 7.40,

and the actual concentrations were

measured spectrophotometrically in the ultraviolet region
et al 1964).

(Storvick

Aliguots of the solutions were stored frozen and thawed

just prior to use.

Solutions of 20 mM SITS and 0.5 mM DIDS

in

isotonic saline were made up just prior to use and kept protected
from light at 0°C;

,

Freshly drawn heparinized blood from one of two healthy males was
separated by centrifugation at lOOOg for 10 min at 7°C.

The buffy

coat was discarded and the RBC were washed with cold isotonic saline.
The RBC were either used directly or preincubated at 0°C.

in isotonic

saline at a concentration of 30% (v/v) v/hich contained either 0.14 mM
SITS or 0.035 mM DIDS.

Incubation solutions of isotonic saline,
plasma,

or bovine serum albumin

(BSA;
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90% (v/v)

heparinized

6 gm/dl NS) with 10 mM glucose

were buffered with MOPS,
0.6 mM.

pH 7.40,

to a final MOPS concentration of

Volumes of the vitamer solutions were added to give

final concentrations indicated in individual experiments.

the

The values

used for vitamer concentrations are calculated values based on the
amount added to a given volumes of incubation solution.

Thus they

may not represent the actual free vitamer concentrations in the
medium because of protein binding.
final concentration of 0.2 mM SITS

In experiments employing SITS,

in the incubation medium was used.

Either normal RBC,

or RBC preincubated with BIDS or SITS were

resuspended in the

incubation solutions

(v/v).

and at timed intervals aliquots were

lOOOg.

to a concentration of 10%

The solutions were incubated at 37°C.

of ice cold isotonic saline,

a

removed,

in a shaking water bath
diluted with 7 volumes

and centrifuged at 7°C.

The pellet was washed with 90 volumes

for 10 min at

ice cold saline and

recentrifuged under identical conditions.

EGOT activity was assayed as
described by Karmen et al

(1955)

follows according to the method
and modified by Solomon

(1978).

The

RBC were lysed by adding 30 ul of the washed RBC pellet to 3 ml of
ice cold distilled water.

After 10 min,

200 ul of the lysate was

added to 2.6 ml of distilled water containing 33 mM d,1-aspartate,
0.067 mg/ml DPNH,

and 67 U/ml malate dehydrogenase.

preincubated 10 min in a shaking water bath at 37°C.

This mixture was
Total EGOT

activity was measured by including PLP at a concentration of 0.5 mM
in the preincubaton solution and preincubating for 30 min.
Thereafter,

200 ul of 100 mM alpha-ketoglutarate
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(in sodium phosphate

buffer, pH 7.5) was added and the consumption of DPNH was followed bymeasurement of the decrease in optical density at a wavelength of 340
nm over 20-30 min at 37°C using a Gilford spectrophotometer with an
automatic chart recorder.

Specific activity of EGOT is expressed as

Units/g Hgb where one Unit is defined as the loss of optical density
at 340 nm per minute divided by the extinction coeffecient for DPNH
at 340 nm of 6.22.

Lysate hemoglobin concentration was determined by

the hemoglobincyanide method (van Kampen and Zijlstra 1961).

When values were determined in triplicate,

the mean is displayed

graphically with the range of plus or minus one standard deviation.
The significance of differences between means was analyzed by the
method of Student's t test.
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RESULTS

Ill.

To determine the

relative abilities of the B6 vitamers

tissues from plasma and activate B6

dependent enzymes,

were resuspended in 90% plasma containing PLP,
incubated for 6 hours.

Aliquots

PMP,

PM,

removed at two hour

to enter

erythrocytes
and PN and

intervals and

assayed for EGOT activation showed marked variation in the relative
abilities of the vitamers to effect GOT activation
mM,

(fig 3).

At 0.67

PLP did not significantly increase GOT activation above control

levels.

In contrast,

the other vitamers were able to increase GOT

activation at concentrations of 0.67 mM with PMP being the most
active followed by PM.

However,

at a concentration of 3.3 mM,

PLP

almost completely activated EGOT.

Since

the total binding capacity of 90% plasma is probably in the

range of 2.7 mM (Lumeng et al 1974),

a PLP concentration of 3.3 mM

would certainly provide a large amount of free PLP in solution.
Thus,

it's not surprising that at such a high concentration,

vitamer should be so active.
PLP will be bound to albumin

Likewise,

at 0.67 mM,

(and perhaps globulin)

this

the majority of
leaving a

fraction free in solution that is quite small and unable to activate
EGOT to the extent that the other vitamers do at 0.67 mM.

These findings are consistent with those of Lumeng et al
and Anderson

(1974)

(1971) who found that the presence of plasma prevents

the entry of PLP into erythrocytes by virtue of binding to plasma
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Figure 3.
plasma

Erythrocyte GOT activation by B6 vitamers

(v/v).
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in 90%

proteins.

Of considerable

vitamers are able
activation.

interest then is the

finding that other B6

to enter the RBC and effect significant GOT

This finding questions

the concept that PLP is the

"principle" B6 vitamer because of its high plasma concentration.
Rather,

this experiment suggests that physiologic levels of other B6

vitamers may enter tissues

to a greater extent and effect a.poenzyme

activation after conversion to active forms.

Although PMP v/ould

appear to be a strong possibility under these experimental
conditions,
vitamers

it is found to constitute only 4% of the plasma B6

(Table

1).

Thus an experiment with PMP,

PM and PN at

equimolar concentrations does not accurately reflect the physiologic
ratios of these vitamer concentrations.

To confirm the

theory that protein binding was responsible

lack of GOT activation with 0.67 mM PLP in plasma,

the previous

experiment was performed in MOPS buffered isotonic saline.
results

>
(figs 4,5)

)
clearly demonstrate

for the

The

that in the absence of plasma,

0.67 mM PLP effects GOT activation almost to the same extent as 3.3
mM PLP.

Not surprisingly,

PMP,

PM and PN are as effective

activating GOT in saline as in plasma

(figs 4,5).

in

This confirms

that

plasma has no effect on these vitamers presumably because of their
inability to form Schiff base adducts with plasma proteins.

The effect of inorganic phosphate on EGOT activation by PLP in
plasma was investigated using a low phosphate concentration
and a moderately high concentration
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(20 mM).

(5 mM)

A higher concentration

GOT (U/gHgb)

3.3 mM PLP

0.67 mM P.MP
0.67 mM PLP
0.67 mM PM

0.67 mM PN

No B6

Hours

Figure 4.

Erythrocyte GOT activation by E>6 vitamers in MOPS

buffered isotonic saline.
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GOT (U/gHgb)

Suspension Medium
Figure 5.

Erythrocyte GOT activation by 1.0 mM PLP or 1.0 mM

PMP in either 90% plasma
after 4 hours

(v/v)

or MOPS buffered isotonic saline

incubation.
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of phosphate was not chosen because of the
plasma volume this would require.
unpublished data)

indicates

Previous data

that at 20 mM,

phosphatase activity by about 42%.
phosphate was

significant diminution of
(Solomon,

phosphate

inhibits

At both concentrations however,

found to have no effect on the activation of GOT by

either 3.8 mM PLP or 7.7 mM PLP

(fig 6).

suggest that under these conditions,

This experiment would

phosphatase activity is either

not essential for transport of PLP into the erythrocyte at these
concentrations or that the residual phosphatase activity is
sufficient to mediate PLP uptake by dephosphorylation and duffusion
of PL.

To investigate an alternative mode of transport,
channel blocking agents was studied.

Preincubating erythrocytes

0.035 mM DIDS resulted in significant alterations
uptake

from plasma.

the use of anion
in

in apparent PLP

In the presence of 1.8 mM PLP there was no

significant difference distinguishable between the DIDS-treated cells
and normal cells.
mM,

However,

at the higher PLP concentration of 3.5

further EGOT activation was noted in control cells but not in

DIDS-treated cells

(fig 7).

This experiment was repeated with DIDS

and v/ith another anion channel blocker,

SITS,

giving the same

results.

When the effects of DIDS and SITS on uptake of 11 mM PL and EGOT
activation were investigated,

no differences between normal cells and

anion channel blocked cells v/ere

found (fig 8).
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Interestingly,

the

GOT (U/gHgb)

8 “I

6-i

Legend
123 No Pi
CZ3 5 mM Pi
UD 20 mM Pi

Figure 6.

Effect of 5 mM and 20 mM phosphate on EGOT

activation by 3.85 mM and 7.7 mM PLP in 76% plasma after 4 hours
incubation.

The differences between the means at each PLP

concentration are not significant
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(p>0.2).
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Effect of DIDS on EGOT activation by PLP in 87%
after 4 hours incubation and PL activation of EGOT.
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Figure 8.
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Effect of DIDS on EGOT activation by PLP and PL in

(v/v)

after 4 hours

incubation.
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activation of EGOT by 3.5 mM PL is significantly less
activation by 1.8 mM PLP

(fig 7).

than the

This is contrary to what would be

expected if cleavage of PLP to PL were

the mechanism responsible

for

the non-anion channel dependent PLP transport.

The results of the previous experiments using DIDS and SITS
indicate anion channels may not be responsible
PLP concentrations less

than 1.3 mM.

for PLP transport at

To further characterize

non-anion channel dependent PLP transport,

the

an experiment was carried

out comparing normal cells to DIDS treated cells using a suspension
medium of bovine serum albumin

(6 gm/dl)

isotonic MOPS buffered saline.

and glucose

The results

(fig 9)

(10 mM)

in

show that DIDS

did not inhibit EGOT activation when the PLP concentration in the
medium v/as 2.4 mM.

In contrast,

incubation with 4.8 mM PLP did not

further increase EGOT activation in DIDS treated cells.
reproduces

This

the observations made using plasma indicating that there
%

l

is not some previously unrecognized element of plasma such as
amino acids which partakes in PLP transport.
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free

GOT (U/gHgb)
0

2

4

6

B6 (mM)

Figure 9.

Effect of DIDS on EGOT activation by PLP in a MOPS

buffered suspension medium of bovine serum albumin (6gm%)
glucose

(10 mM)

in isotonic

saline after 4 hours
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and

incubation.

IV.

DISCUSSION

This study investigated several critical issues

in vitamin B6

metabolism using activation of erythrocyte aspartate-oxaloacetate
transaminase

(EGOT)

as an indicator of intracellular cofactor

availability to vitamin B6 dependent enzymes.
relative abilities of the various vitamers

A comparison of the

to enter the erythrocyte

and effect EGOT activation demonstrated the inability of PLP to enter
the erythrocyte from plasma whereas other vitamers,

particularly PMP,

were quite active.

Previous investigations of PLP entry into the erythrocyte have
also shown that it is not readily transported across the cell
membrane from plasma

(Anderson et al 1971,

Lumeng et al 1974).

observation which was confirmed here questions the
generally accorded to PLP.
shown in figure 2 are

This

importance

The activities of the other vitamers as

in fact much greater than equimolar PLP.

This

raises the important question of which of these could play an
important role in vivo.

Because of serum protein binding,

plasma PLP is unable to enter

erythrocytes in significant amounts in these experiments and also in
the experiments of other investigators.

It is unclear however

whether these events accurately reflect events in vivo.

One critical

assumption is essential to the conclusions drawn from these
experiments.

To claim that PLP remains
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in plasma because it binds to

plasma proteins preferentially over intracellular or membrane binding
sites requires an assumption that equilibrium is
incubation period of these experiments.
established.

In fact,

reached during the

This has not been

data of previous investigators suggest that

PLP may not reach equilibrium within hours but rather over days.
instance,

in the experiments of Lumeng

(1973),

For

continued loss of PLP

from plasma occurs during dialysis over the entire 24 hour period
studied.

Thus the time course of dissociation is quite slow.

Similarly,

dialysis of liver cytosol over 24 hours

liberated only 20%

of hepatic cytosolic PLP from holoenzyme complexes.
that all PLP is reversably bound to enzymes,
is also quite slow.
Hillman

(1979)

The

then this dissociation

in vivo investigations of Solomon and

clearly shov; an unexplained 24-48 hour delay between a

single oral PN dose and a rise
(1979)

If it is assumed

in EGOT activity.

Solomon and Hillman

proposed that the initial drop in EGOT within hours of

intramuscular PLP or, oral PN administration followed by a rise after
days was due to non-specific

inhibitory binding of PLP to the enzyme

followed by redistribution to the active sites.

Thus a delay of days

is seen in the response of EGOT to increased PLP in several different
experimental settings.
added to plasma,
vitro,

One possible explanation for this is that PLP

whether in vivo

requires days

(from liver or by injection)

or in

to dissociate from serum proteins and reach the

active sites of apoenzymes.

Thus,

before more conclusions can be

drawn regarding the thermodynamics of PLP binding,

certain

assumptions regarding the binding kinetics clearly must be
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substantiated or revised.

The

investigations of membrane permeation by PLP using DIDS are

intriguing.

Although Cahantchik

channel blocking agent DIDS
erythrocytes,

(1975)

reports

that the anion

totally prevents PLP entry into

the experiments here demonstrate that there

is a

distinct component of PLP transport which is not affected by anion
channel blockers.

This effect is apparent at PLP concentrations in

the 1.0-1.5 mM range.

This

plasma for PLP which means

is well below the binding capacity of
that the actual amount of PLP free

solution is probably fairly low.
is near or above
blockable

in

Only when the plasma content of PLP

the binding capacity for this vitamer is DIDS

transport observed.

In this case,

the concentration of

free PLP in the medium is much higher and it is only then that the
anion channels appear to play a role in transmembrane PLP passage.

Apparently,

in the more physiologic situation of lov; PLP

concentrations,

a mechanism for PLP transport other than anion

channels obtains.

Investigation of the dephosphorylation-

rephosphorylation mechanism may help resolve

this

issue.

Such

experiments would best be done by inhibiting the phosphatase which is
essential to this mode of transport.
show that at 5 mM and 20 mM,
activation of

The experiments conducted here

phosphate has no effect on PLP

EGOT in spite of its demonstrated inhibitory effect on

the phosphatase.

Unfortunately,

any results found using phosphate

may be confused by the effect phosphate also has intracellularly of
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raising concentrations of organic phosphate esters.

A better

inhibitor of the phosphatase is thus critically important
examine

to further

this postulated mechanism.

Yet another possible mechanism of PLP transport might be coupling
with amino acid transport.

That membranes have specific mechanisms

for amino acid transport has been well documented
1978).

Felig et al

(1973)

(Guidotti et al

have also shown that erythrocytes may act

as a transport form of amino acids.

One could hypothesize

that amino

acid uptake and PLP uptake by erythrocytes are interrelated,

perhaps

by Schiff base complexing between the two and transport of the
adduct.
bovine

However,

the experiment described here using a medium of

serum albumin and glucose

amino acids

instead of plasma suggests

found in plasma are not responsible

channel dependent PLP uptake.
conclusively shov/n how PLP is

for the non-anion

On the other hand,

(Lumeng and Li 1980)

the possibility that an amino acid-PLP Schiff base
investigation.

no one has

released from hepatocytes and although

it is proposed that it does so bound to albumin

form merits

that free

is the

Although Gregory and Kirk

released

(1978)

suggested that pyridoxyllysine may exert an anti-B6 activity,
claim has not been substantiated.

once
this

Thus the possibility that amino

acid-PLP adducts could play an important role physiologically or even
pharmacologically deserves

further attention.
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V.

CONCLUSION

Although a few questions are answered here,
are

raised.

employed,
enzyme,

many more questions

It is clear that under the experimental conditions

there

EGOT,

is marked variability in the activation of a tissue

by the various B6 vitamers.

It is also clear that

blockade of membrane anion channels can alter membrane permeability
of PLP.

But contrary to v/hat was previously found,

this does not

occur at PLP concentrations near the physiologic range.

Further elucidation of the mechanisms involved in PLP
into tissues would thus be essential.

transport

Only with such knowledge can

therapeutically advantageous manipulations of PLP transport be
designed.

That PLP is actually the B6 vitamer deserving this

concentrated attention is,

unfortunately,

also unresolved.

Although

the experiments here; confirm the inability of PLP to enter tissues
from plasma and further demonstrate that PMP and PM are quite active,
a serious issue of kinetics of this

Thus,

before any more theories

plasma are asserted,

interaction is questioned.

regarding the behavior of PLP in

conclusive experiments addressing the time

course of the PLP-plasma interactions are
studies previously cited indicate
plasma over days
that PLP is
activate

imperative.

Because

the

that PLP may equilibrate with

instead of hours,

it remains distinctly possible

indeed the B6 vitamer which enters

the B6-dependent enzymes.
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tissues

from plasma to

This certainly would not have

been demonstrated in these experiments or those of previous
investigators because of v/hat may be grossly insufficient in vitro
incubation periods.
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